Stock listing

Cocrystal Pharma, Inc.

Selected listing: A3DWYX · LSX · EUR · DE

Cocrystal Pharma, Inc. (LS Exchange: A3DWYX), Health Technology. Latest release Sep 9, 2026: Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human…

A3DWYX:LSXEURDEUpdated October 2, 2026

Ticker: LS Exchange: A3DWYX
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: LS Exchange
Currency: EUR

Latest news from Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

September 9, 2026

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

August 17, 2026

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

August 3, 2026

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

June 3, 2026

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

May 26, 2026

All Cocrystal Pharma, Inc. news →

Research Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. company profile

View the public company page for Cocrystal Pharma, Inc. on 6ix.

Cocrystal Pharma, Inc. news

Read company news and market updates connected to Cocrystal Pharma, Inc..

Cocrystal Pharma, Inc. investor events

Find investor webinars, events, and replay context for Cocrystal Pharma, Inc..